{"analyses":[{"ciLowerLimit":"7.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"22.3","groupDescription":"Treatment comparison was based on Miettinen \\& Nurminen method stratified by metastatic at initial diagnosis (FIGO \\[2009\\] stage IVB) (yes or no), bevacizumab use (yes or no), and PD-L1 status (CPS\\<1, CPS 1 to \\<10, or CPS ≥10).","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0001","pValueComment":"No formal hypothesis testing performed; nominal p-value provided for treatment comparison","paramType":"Difference in Percentage","paramValue":"14.9","statisticalMethod":"Miettinen & Nurminen method"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.7","upperLimit":"71.5","value":"66.2"},{"groupId":"OG001","lowerLimit":"45.7","upperLimit":"57.2","value":"51.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"308"},{"groupId":"OG001","value":"309"}],"units":"Participants"}],"description":"ORR was defined as the percentage of the participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters). The ORR per RECIST 1.1 as assessed by Investigator is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"On Day 1 of each 21-day cycle, participants received an intravenous (IV) infusion of pembrolizumab 200 mg for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\\^2 PLUS cisplatin 50 mg/m\\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\\^2 PLUS carboplatin Area Under the Curve (AUC) 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"OG000","title":"Pembrolizumab+Chemotherapy"},{"description":"On Day 1 of each 21-day cycle, participants received an IV infusion of placebo (Normal Saline or Dextrose solution) for up to 35 cycles (up to approximately 2 years) PLUS Investigator choice of chemotherapy for up to 6 cycles (paclitaxel 175 mg/m\\^2 PLUS cisplatin 50 mg/m\\^2 WITH or WITHOUT bevacizumab 15 mg/kg per local label OR paclitaxel 175 mg/m\\^2 PLUS carboplatin AUC 5 for up to 6 cycles, WITH or WITHOUT bevacizumab 15 mg/kg per local label). All treatments were administered until disease progression or toxicity.","id":"OG001","title":"Placebo+Chemotherapy"}],"paramType":"NUMBER","populationDescription":"All randomized participants based on the treatment group to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 46 months","title":"Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}